Summary
The supplied AI statements are price/coverage/biosimilar/market and patent-timing claims rather than prescribing-information claims. The FDA label excerpts provided contain no support for these non-clinical assertions, and the request does not provide exact label-relevant claim text to audit against. No dosing/safety/indication-specific claims were provided that could be confirmed against the provided label.
Category Scores
Accurate Statements
Unsupported Statements
A single 3-month leuprolide acetate injection (Eligard) is sold in the U.S. for about $4,500–$5,000 retail.
No information about U.S. retail pricing is present in the provided FDA-approved prescribing information excerpts.
Generic versions of Eligard ... can be priced around $3,500–$4,000 for the same 3-month supply.
No pricing information for generics/batch pricing is present in the provided label excerpts.
Most commercial insurance plans cover Eligard under oncology or prostate-cancer protocols.
No insurance coverage statements are present in the provided label excerpts.
Commercial insurance copay or coinsurance for Eligard depends on the patient’s benefit tier.
No payer benefit-tier/cost-sharing details are present in the provided label excerpts.
Medicare Part B typically covers Eligard when it is administered by a clinician.
No Medicare coverage statements are present in the provided label excerpts.
Patients pay usual Part B cost-sharing for Eligard.
No cost-sharing details are present in the provided label excerpts.
Biosimilar leuprolide products such as Abarelix and Relugon entered the market in 2024.
No market entry dates or product-brand biosimilar timelines are present in the provided label excerpts.
Biosimilar leuprolide products offer prices 10–20% lower than the brand name.
No comparative pricing statements are present in the provided label excerpts.
In some regions, generic leuprolide acetate ... is available at a further reduced cost.
No regional pricing statements are present in the provided label excerpts.
Compared with other hormonal agents like Goserelin (Zoladex) and Degarelix (Firmagon), Eligard is generally mid-tier in price.
No comparative pricing across other agents is present in the provided label excerpts.
Goserelin 3-month injections average $4,000.
No pricing information for other drugs is present in the provided label excerpts.
Degarelix 3-month costs hover around $5,500.
No pricing information for other drugs is present in the provided label excerpts.
Pfizer’s Prostate Cancer Support Program offers financial help to patients who meet income and insurance criteria.
No patient-assistance program details are present in the provided label excerpts.
The Patient Assistance Fund provides vouchers covering up to 90% of the drug cost for uninsured or under-insured patients.
No voucher/program percentage or eligibility details are present in the provided label excerpts.
Price of Eligard is influenced by manufacturing costs, patent protection, and the competitive landscape.
No discussion of determinants of pricing is present in the provided label excerpts.
Original patents on leuprolide acetate expired in 2016.
No patent-expiration statements are present in the provided label excerpts.
Although leuprolide acetate generics and biosimilars are present, the brand name still commands a premium due to marketing and brand recognition.
No marketing/brand-premium statements are present in the provided label excerpts.
Key patents covering the formulation and administration of leuprolide acetate are set to expire in 2027.
No patent-expiration statements are present in the provided label excerpts.
After 2027, additional generics may enter the market.
No statements about future market entry are present in the provided label excerpts.
This could lower the price by 20–30% over the next few years.
No pricing-change projections are present in the provided label excerpts.
In Canada, a 3-month dose of Eligard costs about CAD 1,200–1,400.
No non-U.S. pricing statements are present in the provided label excerpts.
In the U.K., the NHS supplies Eligard at roughly £300–£400 per cycle.
No UK/NHS procurement pricing statements are present in the provided label excerpts.
Contradictions
Important Omissions
No FDA-label-aligned clinical claims were provided to evaluate (e.g., exact indication language, dosing schedule details, contraindications/warnings/monitoring). If the intent was to describe prescribing-information content, those elements were omitted.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements are non-prescribing-information (primarily pricing/coverage/market/patent-program claims) and do not directly assert dosing, contraindications, monitoring, or safety risks from the label. However, because they are unsupported by the provided label excerpts, they represent potential misinformation risk rather than direct medication risk.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most statements are pricing/insurance/patent/market timing claims that are not supported by the provided FDA-approved prescribing information excerpts.
Suggested Improvement
Limit claims to information explicitly present in the FDA label (e.g., indication, administration route and dosing periods, contraindications, warnings/precautions such as tumor flare, lab monitoring such as testosterone and PSA, and drug interaction statements). Remove or qualify unsupported non-label market and payer/pricing assertions.